Abstract:The human transmembrane protein Transferrin Receptor-1 is regarded as a promising target for the systemic delivery of therapeutic agents, particularly of nucleic acid therapeutics, such as short double stranded RNAs. This ubiquitous receptor is involved in cellular iron uptake, keeping intracellular homeostasis. It is overexpressed in multiple cancer cell types and is internalized via clathrin-mediated endocytosis. In previous studies, a human transferrin receptor-1 RNA aptamer, identified as TR14 ST1-3, was shown to be capable of effectively internalizing into cells in culture and to deliver small, double stranded RNAs in vitro and in vivo, via systemic administration. To understand, at the molecular level, the aptamer binding to the receptor and the impact of conjugation with the therapeutic RNA, a multi-level in silico protocol was employed, including protein-aptamer docking, molecular dynamics simulations and free energy calculations. The competition for the binding pocket, between the aptamer and the natural ligand human Transferrin, was also evaluated. The results show that the aptamer binds to the same region as Transferrin, with residues from the helical domain showing a critical role. Moreover, the conjugation to the therapeutic RNA, was shown not to affect aptamer binding. Overall, this study provides an atomic-level understanding of aptamer association to human Transferrin Receptor-1 and of its conjugation with a short model-therapeutic RNA, providing also important clues for futures studies aiming to deliver other oligonucleotide-based therapeutics via Transferrin Receptor.

Transferrin receptor targeting by de novo sheet extension

De Novo Design of Transmembrane Nanopores

De novo-designed transmembrane proteins bind and regulate a cytokine receptor

Blood-Brain Barrier Transport of Transferrin Receptor-Targeted Nanoparticles

Robust de novo design of protein binding proteins from target structural information alone

Transferrin-conjugated, fluorescein-loaded magnetic nanoparticles for targeted delivery across the blood–brain barrier

Recent Progress Using De Novo Design to Study Protein Structure, Design and Binding Interactions

Pathophysiological aspects of transferrin-A potential nano-based drug delivery signaling molecule in therapeutic target for varied diseases

Targeting the transferrin receptor for brain drug delivery

De novo design of protein interactions with learned surface fingerprints

Targeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis Pathway

In Silico Design and Validation of High-Affinity RNA Aptamers Targeting Epithelial Cellular Adhesion Molecule Dimers

Transferrin receptor 1 targeted nanomedicine for brain tumor therapy

De novo design of drug-binding proteins with predictable binding energy and specificity

In silico analysis of aptamer-RNA conjugate interactions with human transferrin receptor

Improving de novo protein binder design with deep learning

Rational Design of TNFα Binding Proteins Based on the De Novo Designed Protein DS119

What Can De Novo Protein Design Bring to the Treatment of Hematological Disorders?

Diffusing protein binders to intrinsically disordered proteins

De novo design of high-affinity binders of bioactive helical peptides

Ubiquitin-derived artificial binding proteins targeting oncofetal fibronectin reveal scaffold plasticity by β-strand slippage